Allogene Therapeutics (ALLO) financial statements
Allogene Therapeutics reported revenue of $0 in fiscal 2025, down 94.2% a year over 3 years.
Net income was -$191M.
Free cash flow was -$150M.
The diluted share count rose 662% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Allogene Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $114M | $156,000 | $95,000 | $22,000 | $0 |
| Research and development | $152M | $145M | $193M | $220M | $256M | $243M | $192M | $150M |
| Selling, general and admin | $41M | $57M | $65M | $74M | $79M | $72M | $65M | $57M |
| Operating income | -$193M | -$202M | -$258M | -$180M | -$336M | -$328M | -$273M | -$209M |
| Interest expense | $3M | $0 | $0 | — | — | $0 | $181,000 | $1M |
| Pre-tax income | -$212M | -$185M | -$250M | -$257M | — | -$327M | -$257M | -$191M |
| Income tax | -$117,000 | -$331,000 | $0 | $0 | $0 | $0 | $443,000 | $0 |
| Net income | -$212M | -$185M | -$316M | -$182M | -$340M | -$327M | -$258M | -$191M |
| EPS (diluted) | -$7.31 | -$1.83 | -$2.63 | -$1.34 | -$2.38 | -$2.09 | -$1.32 | -$0.87 |
| Diluted shares | 29M | 101M | 120M | 136M | 143M | 157M | 195M | 221M |
| Operating margin | — | — | — | -157.9% | -215087.2% | -344986.3% | -1241813.6% | — |
| Net margin | — | — | — | -159.6% | -218214.1% | -344489.5% | -1170863.6% | — |
Balance sheet
Fiscal years, from Allogene Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $721M | $589M | $1.0B | $810M | $576M | $449M | $373M | $258M |
| Total current assets | $468M | $545M | $845M | $471M | $529M | $459M | $303M | $258M |
| Property, plant and equipment | $9M | $56M | $119M | $123M | $113M | $99M | $86M | $73M |
| Total assets | $774M | $718M | $1.2B | $1.1B | $822M | $643M | $549M | $416M |
| Total current liabilities | $29M | $33M | $94M | $48M | $54M | $37M | $36M | $33M |
| Total liabilities | $71M | $89M | $148M | $126M | $155M | $131M | $127M | $123M |
| Shareholders' equity | $703M | $629M | $1.0B | $925M | $667M | $512M | $422M | $293M |
| Net debt | -$92M | -$175M | -$183M | -$173M | -$62M | -$83M | -$75M | -$52M |
Cash flow
Fiscal years, from Allogene Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$45M | -$137M | -$115M | -$185M | -$221M | -$238M | -$200M | -$149M |
| Capital spending | $3M | $51M | $66M | $21M | $5M | $2M | $694,000 | $386,000 |
| Free cash flow | -$48M | -$188M | -$181M | -$206M | -$226M | -$239M | -$201M | -$150M |
| Stock-based compensation | $19M | $46M | $65M | $81M | $84M | $66M | $52M | $38M |
| Free cash flow margin | — | — | — | -180.8% | -144685.9% | -251841.1% | -913609.1% | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ALLO.
Open ALLO in InvestinglyQuestions
What was Allogene Therapeutics's revenue in 2025?
$0 in fiscal 2025, from its 10-K filing.
How much free cash flow does Allogene Therapeutics generate?
-$150M in fiscal 2025 (operating cash flow minus capital spending).
From Allogene Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.